MNG202
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.542
- ANGIOGENESIS+0.509
- MTORC1_SIGNALING+0.507
- HYPOXIA+0.492
- INFLAMMATORY_RESPONSE+0.492
- IL6_JAK_STAT3_SIGNALING+0.488
- UNFOLDED_PROTEIN_RESPONSE+0.486
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.481
- GLYCOLYSIS+0.424
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.421
Top 10 suppressed
- E2F_TARGETS-0.262
- G2M_CHECKPOINT-0.257
- KRAS_SIGNALING_DN-0.245
- SPERMATOGENESIS-0.190
- WNT_BETA_CATENIN_SIGNALING-0.176
- NOTCH_SIGNALING-0.153
- BILE_ACID_METABOLISM-0.122
- APICAL_SURFACE+0.063
- HEDGEHOG_SIGNALING+0.075
- MITOTIC_SPINDLE+0.086
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.920 |
| 2 | BS_8RHPJ740 | EPN | EPN Tumor | 0.904 |
| 3 | EPT0508 | EPN | Posterior Fossa EPN | 0.904 |
| 4 | s_150324_4b | EPN | Posterior Fossa EPN | 0.900 |
| 5 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.900 |
| 6 | SRR1331579 | GTEX | — | 0.899 |
| 7 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.894 |
| 8 | 5B9D33F5-1B4F-4C06-A73A-CC723C1EF409 | — | — | 0.891 |
| 9 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.890 |
| 10 | BS_2YCJV2VV | low-grade glioma | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.542 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.509 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.507 | Inavolisib | — uncovered |
| HYPOXIA | 0.492 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.492 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.488 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.486 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.481 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.424 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.421 | Inavolisib | — uncovered |
| APOPTOSIS | 0.405 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.399 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.364 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.359 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.355 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.343 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.331 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.324 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.307 | Inavolisib | — uncovered |